Back

Not changes in heart failure therapy but patient characteristics at admission predict unsuccessful guidance of therapy to a target of more than 30% NT-proBNP reduction

29 April 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Biomarkers Natriuretic peptides HFA Premium Access Heart Failure 2017 - 4th World Congress on Acute Heart Failure

About the speaker

Photo
Miss Susan Stienen

Radboud University Medical Centre, Nijmegen (Netherlands (The))

24 More presentations in this session

Presentation thumbnail
The value of NT-proBNP in the diagnosis of cardiac disease in patients with alcoholic liver cirrhosis
Associate Professor P. Lazarev (Moscow, RU)
Abstract Slides
Presentation thumbnail
Sacubitril/valsartan prevents the acute increase of n-terminal brain natriuretic peptide induced by exercise training in subjects with heart failure
Presentation thumbnail
The diagnostic and economic implications of using a plasma nt-probnp of 300 or 400ng/litre as the threshold for ruling out the diagnosis of heart failure in a non selected british population
Doctor J. Webb (London, GB)
Abstract
Presentation thumbnail
Natriuretic peptides for detection of heart failure in patients with atrial fibrillation from the community
Professor F. Rutten (Utrecht, NL)
Abstract
Presentation thumbnail
Diagnostic accuracy of plasma ntprobnp in patients over 80 years of age in a non selected british population
Miss J. Draper (London, GB)
Abstract

Access the full session

Session thumbnail
Poster Session 2 - Biomarkers

The Event

Event poster

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources